CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference




CG Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

IRVINE, Calif.–(BUSINESS WIRE)–#JPM2023CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 4pm Pacific Standard Time. The presentation will be webcast live and available for replay from the news section of CG Oncology’s website at www.cgoncology.com.

About CG Oncology

CG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. To learn more, visit www.cgoncology.com. Follow us on Twitter @cgoncology.

Contacts

Bing Kung

Vice President, Business Development

CG Oncology

bd@cgoncology.com

Media

Kimberly Ha

KKH Advisors

(917) 291-5744

kimberly.ha@kkhadvisors.com